Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.

Karnezis, Tom T

Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. [electronic resource] - The Laryngoscope Mar 2011 - 636-8 p. digital

Publication Type: Journal Article

1531-4995

10.1002/lary.21415 doi


Administration, Intranasal
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--administration & dosage
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Bevacizumab
Combined Modality Therapy
Dose-Response Relationship, Drug
Epistaxis--drug therapy
Female
Humans
Injections
Laser Coagulation
Lasers, Solid-State--therapeutic use
Male
Middle Aged
Nasal Mucosa--drug effects
Nasal Sprays
Recurrence
Retrospective Studies
Telangiectasia, Hereditary Hemorrhagic--drug therapy
Young Adult